Grade 3/4 thrombocytopenia was seen in 32% of the patients. Updated data from the core (n = 166) and extension study (n = 120) of patients receiving momelotinib therapy were recently presented, with response rates of 39% for spleen (not confirmed by imaging studies) and 53% for anemia. 9 The favorable effect on anemia was a distinguishing feature for momelotinib, but the drug was also associated with treatment-emergent peripheral neuropathy.
The main objective of the current study was to re-evaluate the above-mentioned response rates, using the revised IWG-MRT-ELN criteria, wherever possible, and the long-term response durability in 111 MF patients treated on previously published phase-1/2 clinical trials involving momelotinib (CCL09101; NCT00935987) or ruxolitinib (INCB18424-251; NCT00509899). 5, 7 Of note, we were not able to fully implement the 2013 revised response criteria because the treatment protocols at the time did not require imaging studies for confirmation of spleen response or application of the MPN Symptom Assessment Form. Therefore, we advise caution in interpreting our analyses and to not draw definitive conclusions from the current retrospective study. The baseline clinical characteristics of these patients are listed in Table 1 . Treatment eligibility criteria were as previously published 5, 7 and for the most part similar, but the risk distributions were worse for momelotinib, as outlined in Table 1 . Patients receiving momelotinib therapy were older (P = 0.01) and presented with higher risk distribution per the dynamic international prognostic scoring system-plus (P = 0.006). 10 Momelotinib-treated patients also displayed lower platelet (P = 0.004) and leukocyte (P = 0.046) counts and higher incidence of previous exposure to JAK inhibitor therapy (22% vs 2%; P = 0.002), compared to those treated with ruxolitinib. Patients were enrolled into the ruxolitinib study between 10/11/2007 and 2/25/2009, and to the momelotinib study between 11/20/09 and 11/10/10.
No patient (0%) achieved CR and only one (1.7%) momelotinibtreated patient achieved PR ( Table 2 ). Based on revised response assessment that utilized the 2013 IWG-MRT-ELN criteria, wherever possible, CI was documented in 34 (57%) patients treated with momelotinib and 9 (18%) patients treated with ruxolitinib ( Table 2 ). Being evaluable for anemia response was strictly defined by the IWG-MRT criteria 1,2 and required a hemoglobin level of o 10 g/dl or transfusion dependency. Anemia response was 45% for momelotinib and 11% for ruxolitinib. Median duration of anemia response was 13 months (range 3-42+) for momelotinib and 13 months (range 5-21) for ruxolitinib. Median duration of spleen response was 10 months (range 3-43+) for momelotinib and 20 months (range 5-61) for ruxolitinib. The 1-, 2-and 3-year discontinuation rates were 49%, 71% and 86% for ruxolitinib and 25%, 45% and 73% for momelotinib, respectively ( Table 2 ). The major reasons for treatment discontinuation were loss of therapeutic effect, lack of response and druginduced cytopenia.
The current study should not be viewed as a substitute for a prospective randomized comparison of ruxolitinib and momelotinib, which is currently ongoing in patients with MF (ClinicalTrials. gov Identifier: NCT01969838). However, it highlights a number of issues with JAK inhibitor therapy that are unlikely to be resolved with phase-3 studies. First, it is becoming increasingly evident that currently available JAK inhibitors are incapable of inducing CR or PR Accepted article preview online 25 September 2014; advance online publication, 17 October 2014 Letters to the Editor in MF. Second, the salutary effect of ruxolitinib therapy in alleviating constitutional symptoms and reducing spleen size in MF is antagonized by treatment-related cytopenias and that of momelotinib by treatment-emergent peripheral neuropathy. Furthermore, our long-term experience suggests that the benefit from both drugs might not be long-lived. These observations highlight the need for new drugs with alternative mechanism of action.
Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML)
Leukemia (2015) 29, 500-502; doi:10.1038/leu.2014.288
Downstream of tyrosine kinase (DOK) proteins are substrates of protein tyrosine kinases, acting as negative regulators of cell signaling pathways. 1 Loss of DOK2 gene expression has been detected in human lung adenocarcinomas, and mice with Dok2 haploinsufficiency develop lung cancers. 2 Mice lacking both Dok1 and Dok2 genes (the two first described Dok gene family members) present a myeloproliferative chronic myelogenous leukemia-like syndrome. 3, 4 Moreover, genetic ablation of Dok genes in a BCR/ABL transgenic background accelerates the apparition of the blastic crisis and leukemia induced by the BCR-ABL fusion oncoprotein, 3, 4 DOK1 and DOK2 adaptor proteins attenuate RAS/ERK-and PI3K/AKT-dependent signaling pathways involved in myeloid cell proliferation. [3] [4] [5] On the basis of these studies, animal models [2] [3] [4] and data from solid tumors, 2, 6 DOK genes are now considered as tumor suppressors. However, the mutation status of DOK1 and DOK2 genes in patients with chronic myeloproliferative neoplasm (MPN) remains to be defined. Mutations in cell signaling genes have been reported in MPNs. 7 Chronic myelomonocytic leukemia (CMML) belongs to the MPN class. 8 Upon white blood cell count CMML has been subdivided in myelodysplatic (MD-CMML) and myeloproliferative (MP-CMML) subtypes. These two subtypes are associated with different gene expression profiles. 9 Under informed consent, we analyzed the gene mutations in the bone marrow (BM) samples from 30 MD-CMML and 36 MP-CMML patients ( Supplementary Table S1 ). Expectedly, mutations previously reported in CMML patients (such as NRAS, CBL, PTPN11, FLT3, JAK2 and NF1 genes) 7 were present in our MP-CMML cohort. We analyzed somatic mutations in DOK1 and DOK2 genes. Genomic DNA from the BM cells was amplified with six primer pairs covering the entire coding region (exons 1-5) of each DOK gene (Supplementary Material). We identified point mutations in the two DOK genes. For DOK1, two variants were found; L60Q in exon 1 coding for a functional protein-lipid interaction domain, a pleckstrin homology domain, 10 and D263E in exon 5. For DOK2, four variants (2 × R201H, L238P and R215H) were found in 3/66 CMML and 1/2 unclassified myeloproliferative myelodysplastic neoplasm. These DOK2 point mutations are located in exon 4 and the 5' end of exon 5 that code for the phosphotyrosine binding (PTB) domain of the DOK protein. 11 Sorted CD3 + lymphocytes of the peripheral blood from DOK variant patients were only available for the MP-CMML patient with DOK2 L238P mutation. The DOK2 L238P mutation was present in the myeloid cells but not in the lymphoid cells ( Figure 1a) .
A three-dimensional structure model revealed that the L238P substitution would alter the structure of the DOK2 PTB domain, resulting in a loss of stable binding to phosphotyrosyl peptides (Figure 1b ).
DOK2 binds via its PTB domain to tyrosine phosphorylated DOK1 protein. 12 Two arginine residues in positions 200 and 201 Accepted article preview online 25 September 2014; advance online publication, 21 October 2014
